The question of which is the safest range of blood glucose levels for “benefit without harm” was finally answered by the NICE-SUGAR trial in medical ICU patients on intensive (blood glucose levels 4.5–6 mmol/L) vs. conventional glycemic control (blood glucose levels 8–10 mmol/L) by intravenous insulin: mortality in the latter group was actually lower than in the former group; the reason was more frequent episodes of moderate or severe hypoglycemia in the intensive treatment group, which was associated strongly with the risk of death [90]. The gene discussed is INS; the disease is Hypoglycemia.